Overview of Myelodysplastic Syndromes

2008 Nimer, 2008, Myelodysplastic syndromes, Blood, 111, 4841, 10.1182/blood-2007-08-078139 Bennett, 1982, Proposals for the classification of the myelodysplastic syndromes, Br J Haematol, 51, 189, 10.1111/j.1365-2141.1982.tb08475.x Vardiman, 2002, The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, 100, 2292, 10.1182/blood-2002-04-1199 Valent, 2007, Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference, Leuk Res, 31, 727, 10.1016/j.leukres.2006.11.009 Brunning, 2008, Myelodysplastic syndromes/neoplasms, vol. 2, 88 Greenberg, 1997, International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, 15, 2079, 10.1182/blood.V89.6.2079 Malcovati, 2007, Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes, J Clin Oncol, 25, 3503, 10.1200/JCO.2006.08.5696 Malcovati, 2005, Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making, J Clin Oncol, 23, 7594, 10.1200/JCO.2005.01.7038 Bowen, 2008, Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application, J Clin Oncol, 26, 1180, 10.1200/JCO.2007.15.2926 Garcia-Manero, 2008, A prognostic score for patients with lower risk myelodysplastic syndrome, Leukemia, 22, 538, 10.1038/sj.leu.2405070 Schanz, 2012, New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge, J Clin Oncol, 30, 820, 10.1200/JCO.2011.35.6394 Haase, 2007, New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients, Blood, 110, 4385, 10.1182/blood-2007-03-082404 List, 2006, Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion, N Engl J Med, 355, 1456, 10.1056/NEJMoa061292 Kantarjian, 2009, The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?, Cancer, 115, 5202, 10.1002/cncr.24575 Rollison, 2008, Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs, Blood, 112, 10.1182/blood-2008-01-134858 Extermann, 2000, Measurement and impact of comorbidity in older cancer patients, Crit Rev Oncol Hematol, 35, 181, 10.1016/S1040-8428(00)00090-1 Sorror, 2005, Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT, Blood, 106, 2912, 10.1182/blood-2005-05-2004 Naqvi, 2011, Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model, J Clin Oncol, 29, 2240, 10.1200/JCO.2010.31.3353 Kuendgen, 2006, Myelodysplastic syndromes in patients younger than age 50, J Clin Oncol, 12, 5358, 10.1200/JCO.2006.07.5598 Bejar, 2011, Clinical effect of point mutations in myelodysplastic syndromes, N Engl J Med, 364, 2496, 10.1056/NEJMoa1013343 Delhommeau, 2009, Mutation in TET2 in myeloid cancers, N Engl J Med, 360, 2289, 10.1056/NEJMoa0810069 Abdel-Wahab, 2009, Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies, Blood, 114, 144, 10.1182/blood-2009-03-210039 Langemeijer, 2009, Acquired mutations in TET2 are common in myelodysplastic syndromes, Nat Genet, 41, 838, 10.1038/ng.391 Szpurka, 2006, Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation, Blood, 108, 2173, 10.1182/blood-2006-02-005751